Fixed Record Date For Buyback
Record Date for Buyback Pursuant to the Regulation 9 of SEBI (Buy-back of Securities) Regulations, 1998, it may please be noted that, the Buyback Committee at their meeting held today fixed December 8, 2017 as the 'Record Date' for the purpose of determining the entitlement and the names of the Shareholders, who are eligible to participate in the Buyback Offer of the Company. Kindly, take a note of the above in your records. 1. Announcement Of Voting Results For Buyback & 2. Record Date For Buyback
Announcement of Voting Results on Postal Ballot (incl. E-Voting) for Buyback Pursuant to Regulation 44 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a report of the Scrutinizer on Voting Results of the Company's Postal Ballot notice dated September 25, 2017, for approval of Buyback of equity shares by the Company.... Novartis highlights differentiated late stage pipeline at R&D; update & investor event
Novartis has had a strong year in innovation with several key approvals and positive trial readouts. Novartis holds an R&D and investor update in London, which will provide deeper insights into key latestage pipeline Ranjit Shahani steps down at Novartis after two decades
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad
Novartis India Q2 profit up 18% at Rs26 crore
Novartis India announced the resignation of its vice chairman and managing director Ranjit Shahani with effect from 28 February 2018 Resignation of Managing Director
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that, Mr. Ranjit Shahani, Vice Chairman & Managing Director, informed the Board of Directors, at their meeting held today, of his decision to step down from the office of Vice Chairman and Managing Director effective February 28, 2018 (close of business hours) after 20 years of distinguished service with the Company. Outcome of Board Meeting
We refer to our letter dated October 10, 2017, informing you of our Board Meeting that was scheduled for today. Please note that the Board of Directors of Novartis India Limited met today and considered financial results of the Company for second quarter and half year ended September 30, 2017. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 3.45 p.m.... Novartis MONALEESA7 trial of Kisqali in advanced/metastatic breast cancer meets primary endpoint
Novartis announced positive topline results from the global MONALEESA7 trial, the second phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. The MONALEESA7 trial met its Novartis presents positive data from FUTURE 5 study of Cosentyx to treat psoriatic arthritis at 2017 ACR/ARHP meeting
Novartis announced results from the FUTURE 5 study showing Cosentyx (secukinumab) reduced the signs and symptoms of psoriatic arthritis (PsA) while significantly inhibiting the progression of joint structural damage in PsA Sandoz biosimilar Erelzi matches efficacy, safety profile of reference biologic in rheumatoid arthritis
Sandoz, a Novartis division and the global leader in biosimilars, announces results from the EQUIRA study. The phase III comparative safety and efficacy study shows that Sandoz biosimilar Erelzi